Dr. Lundstrom is a molecular biologist by training with unique combined experience in academia and the pharmaceutical/biotech industry. He is the author of more than 200 research articles, reviews and book chapters and a frequent invited speaker at international conferences. In parallel, he has long-term experience of large pharmaceutical organizations (Glaxo, Roche), medium-size companies (Cetus, Flamel Technologies) as well as start-ups (Regulon Inc., BioXtal). Dr. Lundstrom has a vast experience in project coordination by serving as the Scientific Coordinator of the privately funded structural genomics network MePNet (2001-04) and as a Steering Committee Member of the EU-funded E-MeP initiative. These activities involved close interaction with the pharmaceutical industry and fundraising activities. Dr. Lundstrom has lived in Switzerland since 1992 except for a short stay in UK in 1995-96. PanTherapeutics will profit from an experienced management team (see below) and due to the excellent scientific contacts from an attractive combination of strong academic research teams and a solid dedication to commercialization of research discoveries. PanTherapeutics has already initiated proof-of-concept studies. PanTherapeutics possesses an open-minded, innovative and pioneering approach.
A PHILANTHROPIC INITIATIVE OF A PRIVATE CONSORTIUM
Turning scientific innovation into entrepreneurial activity and job creation is the basis of societal and economical prosperity. In the very early stages, startups bear very high risks that are neither carried by public money nor by private investors. Supporting seed stage startups fills a crucial gap and is therefore purely philanthropic.
Read more about the Foundation of Founders
